Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2.
Smit MJ, Sander AF, Ariaans MBPA, Fougeroux C, Heinzel C, Fendel R, Esen M, Kremsner PG, Ter Heine R, Wertheim HF, Idorn M, Paludan SR, Underwood AP, Binderup A, Ramirez S, Bukh J, Soegaard M, Erdogan SM, Gustavsson T, Clemmensen S, Theander TG, Salanti A, Hamborg M, de Jongh WA, McCall MBB, Nielsen MA, Mordmüller BG; COUGH-1 trial study group. Smit MJ, et al. Among authors: underwood ap. Lancet Microbe. 2023 Mar;4(3):e140-e148. doi: 10.1016/S2666-5247(22)00337-8. Epub 2023 Jan 18. Lancet Microbe. 2023. PMID: 36681093 Free PMC article. Clinical Trial.
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
Ramirez S, Fernandez-Antunez C, Galli A, Underwood A, Pham LV, Ryberg LA, Feng S, Pedersen MS, Mikkelsen LS, Belouzard S, Dubuisson J, Sølund C, Weis N, Gottwein JM, Fahnøe U, Bukh J. Ramirez S, et al. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0009721. doi: 10.1128/AAC.00097-21. Epub 2021 Jun 17. Antimicrob Agents Chemother. 2021. PMID: 33903110 Free PMC article.
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
Underwood AP, Sølund C, Fernandez-Antunez C, Villadsen SL, Winckelmann AA, Bollerup S, Mikkelsen LS, Sørensen AL, Feng S, Fahnøe U, Lassauniere R, Fomsgaard A, Ramirez S, Weis N, Bukh J. Underwood AP, et al. EBioMedicine. 2021 Sep;71:103519. doi: 10.1016/j.ebiom.2021.103519. Epub 2021 Aug 19. EBioMedicine. 2021. PMID: 34419923 Free PMC article.
Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.
Sølund C, Underwood AP, Fernandez-Antunez C, Bollerup S, Mikkelsen LS, Villadsen SL, Fahnøe U, Winckelmann AA, Feng S, Nørløv Vinten CA, Dalegaard MI, Vizgirda G, Sørensen AL, Ramirez S, Bukh J, Weis N. Sølund C, et al. Among authors: underwood ap. Vaccines (Basel). 2022 Jan 4;10(1):75. doi: 10.3390/vaccines10010075. Vaccines (Basel). 2022. PMID: 35062736 Free PMC article.
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.
Underwood AP, Sølund C, Fernandez-Antunez C, Villadsen SL, Mikkelsen LS, Fahnøe U, Bollerup S, Winckelmann AA, Schneider UV, Binderup A, Vizgirda G, Sørensen AL, Vinten CN, Dalegaard MI, Ramirez S, Weis N, Bukh J. Underwood AP, et al. EBioMedicine. 2023 Mar;89:104475. doi: 10.1016/j.ebiom.2023.104475. Epub 2023 Mar 2. EBioMedicine. 2023. PMID: 36870117 Free PMC article.
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.
Underwood AP, Sølund C, Jacobsen K, Binderup A, Fernandez-Antunez C, Mikkelsen LS, Inekci D, Villadsen SL, Castruita JAS, Pinholt M, Fahnøe U, Ramirez S, Brix L, Weis N, Bukh J. Underwood AP, et al. Front Immunol. 2024 Mar 20;15:1353353. doi: 10.3389/fimmu.2024.1353353. eCollection 2024. Front Immunol. 2024. PMID: 38571939 Free PMC article.
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals.
Offersgaard A, Duarte Hernandez CR, Zhou Y, Duan Z, Gammeltoft KA, Hartmann KT, Fahnøe U, Marichal-Gallardo P, Alzua GP, Underwood AP, Sølund C, Weis N, Bonde JH, Christensen JP, Pedersen GK, Jensen HE, Holmbeck K, Bukh J, Gottwein JM. Offersgaard A, et al. Among authors: underwood ap. Sci Rep. 2024 Jul 24;14(1):17039. doi: 10.1038/s41598-024-67570-0. Sci Rep. 2024. PMID: 39048693 Free PMC article.
Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions.
Pham LV, Underwood AP, Binderup A, Fahnøe U, Fernandez-Antunez C, Lopez-Mendez B, Ryberg LA, Galli A, Sølund C, Weis N, Ramirez S, Bukh J. Pham LV, et al. Among authors: underwood ap. Emerg Microbes Infect. 2024 Dec;13(1):2412643. doi: 10.1080/22221751.2024.2412643. Epub 2024 Nov 13. Emerg Microbes Infect. 2024. PMID: 39392057 Free PMC article.
53 results